Novo Nordisk A/S
NVO
$54.24
-$0.06-0.11%
NYSE
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
P/E (TTM)
EPS (TTM)
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 39.35% | 10.71% | 27.24% | 22.55% | 1.92% |
| Total Depreciation and Amortization | 117.26% | 71.93% | -87.76% | -14.08% | -7.60% |
| Total Amortization of Deferred Charges | -- | -- | 18.52% | -- | -- |
| Total Other Non-Cash Items | -69.73% | 316.98% | -514.56% | 503.01% | 66.81% |
| Change in Net Operating Assets | -49.14% | -65.65% | 91.02% | -197.39% | 342.44% |
| Cash from Operations | -14.86% | 66.44% | 27.50% | 8.01% | 74.52% |
| Capital Expenditure | -47.62% | -53.45% | -69.44% | -109.82% | -75.90% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 104.54% | -47.40% | 218.96% | -19.56% | -178.06% |
| Cash from Investing | 27.55% | -263.42% | -513.58% | -59.27% | -120.49% |
| Total Debt Issued | 31.07% | -- | -- | -- | -- |
| Total Debt Repaid | -1,183.53% | -3,695.58% | -21.97% | -103.83% | -1,254.69% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 100.00% | 51.06% | 23.26% | 60.84% | 15.57% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -19.67% | -- | -17.08% | -- |
| Other Financing Activities | -402.67% | 402.67% | -- | -- | -57.03% |
| Cash from Financing | -392.13% | 120.02% | 460.47% | 6.38% | 230.87% |
| Foreign Exchange rate Adjustments | -2,133.13% | -289.35% | 439.62% | -184.00% | 163.81% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -146.49% | 379.58% | -164.33% | -49.03% | 591.74% |